Navigation Links
BioMed Realty Trust Closes New $18 Million Secured Loan
Date:6/22/2009

SAN DIEGO, June 22 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR) announced today the closing of a new $18 million loan secured by the company's 9865 Towne Centre Drive property in San Diego.

Construction of 9865 Towne Centre Drive, a state-of-the-art laboratory and office facility, was completed in the second quarter of 2008, and the building has since received LEED(R) Silver certification for Core and Shell from the U.S. Green Building Council. The facility was built for, and is fully leased to, Illumina, Inc., one of San Diego's largest biotechnology companies, which is focused on developing, manufacturing and marketing next-generation tools for the large-scale analysis of genetic variation and biological function. Illumina leases a total of approximately 193,000 square feet through October 2023 at the Towne Centre Drive campus in San Diego.

Kent Griffin, BioMed's President and Chief Financial Officer, commented, "We are pleased with our continued support from Washington Capital Management, Inc. and the successful completion of this financing, which was negotiated and completed in the midst of an extremely challenging global credit market environment. Our ability to secure funding for this property is further testament to BioMed's proven business strategy of developing, owning and operating world-class research facilities in the core life science markets for premier biotechnology and pharmaceutical companies."

About BioMed Realty Trust

BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry(R). The company's tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed Realty Trust owns or has interests in 69 properties, representing 112 buildings with approximately 10.5 million rentable square feet, including approximately 640,000 square feet of development in progress. The company also owns undeveloped land parcels adjacent to existing properties that it estimates can support up to 1.4 million rentable square feet. The company's properties are located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey, which have well-established reputations as centers for scientific research.

About LEED(R)

The Leadership in Energy and Environmental Design (LEED(R)) Green Building Rating System(TM) encourages and accelerates global adoption of sustainable green building and development practices through the creation and implementation of universally understood and accepted tools and performance criteria. LEED(R) is a third-party certification program and the nationally accepted benchmark for the design, construction and operation of high performance green buildings. LEED(R) gives building owners and operators the tools they need to have an immediate and measurable impact on their buildings' performance.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation: general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company's target markets; risks associated with the availability and terms of financing, the use of debt to fund acquisitions and developments, and the ability to refinance indebtedness as it comes due; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; risks and uncertainties affecting property development and construction; risks associated with downturns in the national and local economies, increases in interest rates, and volatility in the securities markets; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company's dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMed Realty Trust, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
2. Biomedtex Inc. Announces A. Marc Rocca as President and CEO
3. Hopes, Predictions and Realities: Is Biomedical Research Delivering On Its Promises?
4. Dr. Andrew K. Palmer Joins BMEs (BioMedical Enterprises, Inc.) Board of Directors
5. BioMed Realty Trust to Report 2007 Third Quarter Results
6. BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the OSSArc(TM) Anatomic Residual Compression Implant
7. Response Biomedical Corporation Receives Conditional Listing Approval from the Toronto Stock Exchange
8. BioMed Realty Trust Reports Third Quarter 2007 Financial Results
9. LA BioMed research finds simpler way to assess breast cancer risk
10. LA BioMed researchers find few emergency rooms fully equipped for pediatric patients
11. BioMed Realty Trust Declares Fourth Quarter 2007 Common Stock and Preferred Stock Dividends
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... , ... December 07, 2016 , ... Levels of a ... damage, according to a study appearing online in the journal Radiology. , Heart disease ... to increase significantly due to the rapidly aging population. Damage to both organs often ...
(Date:12/7/2016)... ... , ... They are musicians and librarians, fashion designers and fitness instructors, actors, ... England and around the nation. What do they have in common? All have been ... and compelling new photographic exhibit debuting Friday, December 9 at Logan International Airport in ...
(Date:12/7/2016)... Hollywood, Fl (PRWEB) , ... December 07, 2016 , ... When it came time to ... new heart. Just 40 minutes later, the Pediatric Heart Transplant team at Joe ... true making the Weston teen the hospital’s 30th heart transplant recipient. , “He was ...
(Date:12/7/2016)... ... December 07, 2016 , ... ODU, ... to the US market its advanced highly customizable contact technology solutions. , ODU ... These advanced technologies are ideal for a wide range of applications that require ...
(Date:12/7/2016)... Arbor, MI (PRWEB) , ... December 07, 2016 ... ... insurance and financial consultation services from offices located in South Lyon, Dewitt, Williamston, ... to benefit a basketball coach who needs treatment for a brain tumor. , ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... Dec. 6, 2016 A new study released ... (AIR 340B) projects the 340B Drug Pricing Program will continue ... time it is expected to exceed $23 billion in total ... 340B purchases surpass current Medicare Part B drug reimbursement purchases ... study – based on analysis of data on total drug ...
(Date:12/6/2016)... , Dec. 6, 2016 /PRNewswire/ - InMed ... progress today on its R&D program in the ... obstructive pulmonary disease (COPD). In June, 2015 InMed ... tool to identify the targets and potential active ... of COPD. Subsequently, with in vitro assays using ...
(Date:12/6/2016)... Tenn , Dec. 6, 2016  In response ... dependent on opioids every 25 minutes, a respected group ... company that will provide a holistic suite of services ... Based on his own experience trying to ... social entrepreneur Justin Lanning launched 180 ...
Breaking Medicine Technology: